The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Lymphoma cellular therapy update
Peter Borchmann, MD , University Hospital Cologne, Cologne, Germany, gives an update on cellular therapy for the treatment of lymphoma. Specifically discussed is the UK-based ALEXANDER study (NCT03287817) of AUTO3, a bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
